Several studies have demonstrated paclitaxel-induced inhibition of proliferation and migration of vascular smooth muscle cells (SMC) from Taxol-eluting stents and poly (lactide) (PLA), poly (glycolide) (PGA), poly (caprolactone) (PCL) or their mixture have been used as a drug-loading matrix. Polycaprolactone (PCL), a semi-crystalline linear reabsorbable aliphatic polyester, is subjected to biodegradation because of the susceptibility of its aliphatic ester linkage to hydrolysis. The products generated are either metabolized via the tricarboxylic acid (TCA) cycle or eliminated by direct renal secretion. However, applications of PCL might be limited because degradation and resorption kinetics of PCL are considerably slower than other aliphatic polyester due to its hydrophobic character and high crystallinity. In this study, we have developed PCL network-based drug eluting stent by in situ crosslinking of PCL macromers on stent surface. PCL networks showed faster degradation, and higher compressive modulus and compressive recovery ratios than those of PCL itself because of their low crystallinity and the modification of terminal groups. PCL macromer was obtained by the reaction of PCL diol with acryloyl chloride and novel biodegradable PCL networks were prepared through photopolymerization of the PCL macromer. Drug release kinetics was shown to be linear depending on the density of PCL network. Blood compatibility was investigated by using porcine peripheral blood collected in EDTA tube, and leukocytes adhered on the surface of the devices was observed by SEM. It was shown that PCL network coating on the stent surface does not induce the lysis or aggregation of blood cells, which was also demonstrated by SEM images. The prevention of neointima formation will be tested after implantation of Taxol-loaded, PCL network-coated stents.